Patents Assigned to Changzhou Pharmaceutical Factory
  • Patent number: 10258574
    Abstract: A method for preparing an itraconazole formulation including: dissolving a mixture of itraconazole and L-ascorbic acid with a mixed solvent of dichloromethane and methanol, adding a hydroxypropyl methylcellulose and a pluronic F-127 and then dichloromethane into the mixed solvent to obtain a raw material solution; feeding a carbon dioxide into a crystallization autoclave in a supercritical fluid crystallization equipment system through a pressure regulating valve; spraying the solution into the crystallization autoclave via a spray nozzle, separating out composite particles from the solution and collecting the composite particles at a bottom of the crystallization autoclave, and encapsulating the composite particles to obtain a itraconazole formulation with decreased particle size and increased bioavailability.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: April 16, 2019
    Assignees: CHANGZHOU PHARMACEUTICAL FACTORY CO., LTD., CRYSTEC LTD.
    Inventors: Xuezhi Yin, Linda Sharon Daintree, Sheng Ding, Daniel Mark Ledger, Bing Wang, Wenwen Zhao, Wei Wu, Jiansheng Han
  • Publication number: 20180263912
    Abstract: A method for preparing an itraconazole formulation including: dissolving a mixture of itraconazole and L-ascorbic acid with a mixed solvent of dichloromethane and methanol, adding a hydroxypropyl methylcellulose and a pluronic F-127 and then dichloromethane into the mixed solvent to obtain a raw material solution; feeding a carbon dioxide into a crystallization autoclave in a supercritical fluid crystallization equipment system through a pressure regulating valve; spraying the solution into the crystallization autoclave via a spray nozzle, separating out composite particles from the solution and collecting the composite particles at a bottom of the crystallization autoclave, and encapsulating the composite particles to obtain a itraconazole formulation with decreased particle size and increased bioavailability.
    Type: Application
    Filed: September 8, 2015
    Publication date: September 20, 2018
    Applicants: CHANGZHOU PHARMACEUTICAL FACTORY CO., LTD., CRYSTEC LTD.
    Inventors: Xuezhi YIN, Linda Sharon DAINTREE, Sheng DING, Daniel Mark LEDGER, Bing WANG, Wenwen ZHAO, Wei WU, Jiansheng HAN
  • Patent number: 8765947
    Abstract: A preparation method of rosuvastatin calcium (Formula 1), which can be used for the production of medicament lowering the levels of LDL-cholesterol and triglycerides in vivo, is provided. Such preparation method is suitable for industrial production. Furthermore, the intermediate crystallines used in the preparation method are provided.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: July 1, 2014
    Assignee: Changzhou Pharmaceutical Factory
    Inventors: Benshun Chen, Bing Wang, Xiaofeng Jin, Lin Zou
  • Patent number: 8653265
    Abstract: A preparation method of rosuvastatin calcium (Formula 1), which can be used for the production of medicament lowering the levels of LDL-cholesterol and triglycerides in vivo, is provided. Such preparation method is suitable for industrial production. Furthermore, the intermediate crystallines used in the preparation method are provided.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: February 18, 2014
    Assignee: Changzhou Pharmaceutical Factory
    Inventors: Benshun Chen, Bing Wang, Xiaofeng Jin, Lin Zou
  • Publication number: 20130231509
    Abstract: Disclosed are methods for preparation of two pharmaceutical intermediates (I, II) of Aliskiren, said intermediates are obtained by reacting compound of formula I or II and tribromophosphorus oxide. The method replaces the method in the prior art which is using column chromatopraphy to produce the compounds I and II, and overcomes the defect that the method in the prior art hardly carry out in a large-scale industrial production. The product can be purified by recrystallization or vacuum distillation, and the chemical purity of the product is good.
    Type: Application
    Filed: June 16, 2011
    Publication date: September 5, 2013
    Applicant: CHANGZHOU PHARMACEUTICAL FACTORY
    Inventors: Xuezhi Yin, Bing Wang, Ying Ji, Mingyuan Liu
  • Publication number: 20130197224
    Abstract: A preparation method of rosuvastatin calcium (Formula 1), which can be used for the production of medicament lowering the levels of LDL-cholesterol and triglycerides in vivo, is provided. Such preparation method is suitable for industrial production. Furthermore, the intermediate crystallines used in the preparation method are provided.
    Type: Application
    Filed: March 5, 2013
    Publication date: August 1, 2013
    Applicant: CHANGZHOU PHARMACEUTICAL FACTORY
    Inventor: Changzhou Pharmaceutical Factory
  • Publication number: 20110124864
    Abstract: A preparation method of rosuvastatin calcium (Formula 1), which can be used for the production of medicament lowering the levels of LDL-cholesterol and triglycerides in vivo, is provided. Such preparation method is suitable for industrial production. Furthermore, the intermediate crystallines used in the preparation method are provided.
    Type: Application
    Filed: May 27, 2009
    Publication date: May 26, 2011
    Applicant: CHANGZHOU PHARMACEUTICAL FACTORY
    Inventor: Benshun Chen
  • Patent number: 7608587
    Abstract: The present invention relates to an Exendin 4 polypeptide fragment, which has hypoglycemic activity, and can be used for the treatment of type II diabetes mellitus. The polypeptide sequence described herein is HGEGTX1TSDLSKQX2EEEAVX3LFIEWLKNGX4PX5, where X1 represents Phe or Tyr, X2 represents Met, Ile or Leu, X3 represents Lys, X4 represents Gly or deletion, X5 represents Arg or deletion. Additionally, the present invention relates to a method for the Exendin 4 polypeptide fragment preparation.
    Type: Grant
    Filed: August 1, 2006
    Date of Patent: October 27, 2009
    Assignee: Changzhou Pharmaceutical Factory
    Inventors: Xiaopeng Ma, Bing Wang, Shaoqi Xi